| Citation: |
CHEN Shu, CHEN Jie, CHANG Xin, WU Jian. Analysis of risk factors for primary Sjögren's syndrome complicated with hematological involvement[J]. Journal of Clinical Medicine in Practice, 2023, 27(3): 91-96, 102. DOI: 10.7619/jcmp.20222505
|
To analyze clinical characteristics of patients with primary Sjögren's syndrome (pSS) complicated with hematological damage and to established the prediction models.
The clinical characteristics and laboratory tests imaging examinations of 183 pSS patients were collected. A comparative analysis of pSS patients with hematological damage (n=109) or without hematological damage(n=74)was performed. Logistic regression was used to analyze the related factors of patients with pSS complicated with blood system damage. Prediction models of primary Sjögren's syndrome with hematological involvement based on artificial neural network (ANN) and multi-Logistic regression (MLR) were established, the receiver operating characteristic curve was drawn; and the area under the curve (AUC) and the basic parameters of the two models were compared to evaluate their predictive effectiveness of the models.
Logistic regression analysis showed that liver involvement (OR=0.191, P < 0.05, 95%CI, 0.070 to 0.524), skin involvement (OR=0.292, P < 0.05, 95%CI, 0.121 to 0.704), hypoalbuminemia (OR=0.840, P < 0.05, 95%CI, 0.743 to 0.948), hypokalemia (OR=0.351, P < 0.05, 95%CI, 0.145 to 0.846), high immune globulin (IgM)(OR=1.732, P < 0.05, 95%CI, 1.085 to 2.765), high erythrocyte sedimentation rate (ESR) (OR=1.028, P < 0.05, 95%CI, 1.005 to 1.051) and positive anti-SSA antibodies (OR=0.21, P < 0.05, 95%CI, 0.052 to 0.828)were risk factors associated with hematologic involvement in patients with pSS. There was no significant difference between MLR and ANN models in predicting platelet and leukocyte decline (P>0.05). ANN model was better than MLR model in predicting hemoglobin decline, and the difference was statistically significant (P < 0.05).
Patients with pSS are more likely to suffer hematologic damage. Dysfunction of liver, skin involvement, hypoalbuminemia, hypokalemia, high IgM, high ESR and positive anti-SSA antibodies in clinical works are risk factors for blood system involvement in patients with pSS. ANN and MLR models are two validated predictive modeling tools developed based on the original data from this study, and could be considered for clinical application.
| [1] |
NEGRINI S, EMMI G, GRECO M, et al. Sjögren's syndrome: a systemic autoimmune disease[J]. Clin Exp Med, 2022, 22(1): 9-25. doi: 10.1007/s10238-021-00728-6
|
| [2] |
高波, 周磊, 高泉. 伴有血小板减少的原发性干燥综合征患者的临床特点分析[J]. 实用临床医药杂志, 2016, 20(3): 176-177. doi: 10.7619/jcmp.201603066
|
| [3] |
MCGINN T G, GUYATT G H, WYER P C, et al. Users' guides to the medical literature: XXⅡ: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group[J]. JAMA, 2000, 284(1): 79-84. doi: 10.1001/jama.284.1.79
|
| [4] |
TANG Z H, LIU J, ZENG F, et al. Comparison of prediction model for cardiovascular autonomic dysfunction using artificial neural network and logistic regression analysis[J]. PLoS One, 2013, 8(8): e70571. doi: 10.1371/journal.pone.0070571
|
| [5] |
BAXT G W. Use of an Artificial Neural Network for Data Analysis in Clinical Decision-Making: The Diagnosis of Acute Coronary Occlusion. Neural Computation[J]. 1990, 2(4): 480-489.
|
| [6] |
KULKARNI H, THANGAM M, AMIN A P. Artificial neural network-based prediction of prolonged length of stay and need for post-acute care in acute coronary syndrome patients undergoing percutaneous coronary intervention[J]. Eur J Clin Invest, 2021, 51(3): e13406.
|
| [7] |
VITALI C, BOMBARDIERI S, JONSSON R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis, 2002, 61(6): 554-558. doi: 10.1136/ard.61.6.554
|
| [8] |
DE LONG J B, SHLEIFER A, SUMMERS L H, et al. Noise trader risk in financial markets[J]. Journal of political Economy, 1990, 98(4): 703-738. doi: 10.1086/261703
|
| [9] |
NOCTURNE G, MARIETTE X. Advances in understanding the pathogenesis of primary Sjögren's syndrome[J]. Nat Rev Rheumatol, 2013, 9(9): 544-556. doi: 10.1038/nrrheum.2013.110
|
| [10] |
VIVINO F B. Sjögren's syndrome: clinical aspects[J]. Clin Immunol, 2017, 182: 48-54. doi: 10.1016/j.clim.2017.04.005
|
| [11] |
BAIMPA E, DAHABREH I J, VOULGARELIS M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjögren's syndrome: clinical and pathophysiologic aspects[J]. Medicine: Baltimore, 2009, 88(5): 284-293. doi: 10.1097/MD.0b013e3181b76ab5
|
| [12] |
ZHANG W, WANG F, WANG H, et al. Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases[J]. Clin Rheumatol, 2018, 37(12): 3337-3344. doi: 10.1007/s10067-018-4312-y
|
| [13] |
COPPO P, SIBILIA J, MALOISEL F, et al. Primary Sjögren's syndrome associated agranulocytosis: a benign disorder?[J]. Ann Rheum Dis, 2003, 62(5): 476-478. doi: 10.1136/ard.62.5.476
|
| [14] |
RAMOS-CASALS M, FONT J, GARCIA-CARRASCO M, et al. Primary Sjögren's syndrome: hematologic patterns of disease expression[J]. Medicine: Baltimore, 2002, 81(4): 281-292. doi: 10.1097/00005792-200207000-00004
|
| [15] |
MANDL T, BREDBERG A, JACOBSSON L T, et al. CD4+ T-lymphocytopenia: a frequent finding in anti-SSA antibody seropositive patients with primary Sjögren's syndrome[J]. J Rheumatol, 2004, 31(4): 726-728.
|
| [16] |
曹京旌, 宁晓然, 闫永龙. 干燥综合征患者血液系统受损与自身抗体相关性研究[J]. 河北医药, 2018, 40(6): 882-885, 889. https://www.cnki.com.cn/Article/CJFDTOTAL-HBYZ201806019.htm
|
| [17] |
FOX R I, FOX C M, GOTTENBERG J E, et al. Treatment of Sjögren's syndrome: current therapy and future directions[J]. Rheumatology: Oxford, 2021, 60(5): 2066-2074. doi: 10.1093/rheumatology/kez142
|
| [18] |
LUO J, LUO J, XU S, et al. Clinical features and potential relevant factors of renal involvement in primary Sjögren's syndrome[J]. Int J Rheum Dis, 2019, 22(2): 182-190. doi: 10.1111/1756-185X.13429
|
| [19] |
PERTOVAARA M, KORPELA M, KOURI T, et al. The occurrence of renal involvement in primary Sjögren's syndrome: a study of 78 patients[J]. Rheumatology: Oxford, 1999, 38(11): 1113-1120. doi: 10.1093/rheumatology/38.11.1113
|
| [20] |
XU C, LI Y, YING H, et al. Presence of serum autoantibodies to vacuolar H+-ATPase in patients with renal tubular acidosis[J]. Int J Rheum Dis, 2019, 22(5): 805-814. doi: 10.1111/1756-185X.13518
|
| [21] |
BOSSINI N, SAVOLDI S, FRANCESCHINI F, et al. Clinical and morphological features of kidney involvement in primary Sjögren's syndrome[J]. Nephrol Dial Transplant, 2001, 16(12): 2328-2336. doi: 10.1093/ndt/16.12.2328
|
| [22] |
ZHOU J G, QING Y F, JIANG L, et al. Clinical analysis of primary Sjögren's syndrome complicating anemia[J]. Clin Rheumatol, 2010, 29(5): 525-529. doi: 10.1007/s10067-009-1366-x
|
| [23] |
LIU Y, CHEN S, SUN Y, et al. Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: a retrospective study[J]. Medicine: Baltimore, 2016, 95(50): e5565. doi: 10.1097/MD.0000000000005565
|
| [24] |
DE SANTIS M, CROTTI C, SELMI C. Liver abnormalities in connective tissue diseases[J]. Best Pract Res Clin Gastroenterol, 2013, 27(4): 543-551. doi: 10.1016/j.bpg.2013.06.016
|
| [25] |
吴侗, 周彬, 龙丽, 等. 血小板生成素及其抗体与原发性干燥综合征患者血小板减少的相关性研究[J]. 华西医学, 2016, 31(5): 871-874. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYX201605020.htm
|
| [26] |
MARCUCCI R, ROMANO M. Thrombopoietin and its splicing variants: structure and functions in thrombopoiesis and beyond[J]. Biochim Biophys Acta, 2008, 1782(7/8): 427-432.
|
| [27] |
ZIAKAS P D, PAPADAKI H A, PSYLLAKI M, et al. Anti-thrombopoietin antibodies suppress megakaryocytic colony formation in vitro in patients with systemic lupus erythaematosus[J]. Ann Rheum Dis, 2008, 67(11): 1643-1648. doi: 10.1136/ard.2007.087478
|
| [28] |
KATSUMATA Y, SUZUKI T, KUWANA M, et al. Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis[J]. Arthritis Rheum, 2003, 48(6): 1647. doi: 10.1002/art.10965
|
| [29] |
冯红梅, 蔡祥胜, 杨兆收, 等. 血小板抗体产生的影响因素分析[J]. 广东药科大学学报, 2019, 35(5): 674-678. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYX201905020.htm
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: